

August 20, 2021

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI - 400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI - 400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

We refer to our letter dated August 12, 2021 informing you that the Company had entered into binding agreements with Cronus Pharma Specialities India Private Limited (Cronus Pharma) for acquisition of 51% ownership in Cronus Pharma by subscribing to 95,059,963 equity shares of Rs.10/- each at a premium of Rs.34.18 per equity share aggregating to Rs.420 crores.

The Board of Directors in its meeting held today has approved the termination of the aforesaid agreements and the parties have mutually agreed and terminated the said agreements.

Please take the information on record.

Thanking you,

Yours faithfully,  
**For AUROBINDO PHARMA LIMITED**

  
**B. Adi Reddy**  
Company Secretary

